FUJIFILM Europe will be attending this year’s European Congress of Pathology (ECP) – taking place in Basel, Switzerland, from the 3rd to the 7th of September – where the Medical Informatics team will be showcasing Inspirata’s Dynamyx™ software.
Digital pathology solutions offer significant logistical and operational benefits compared to traditional methods. Digitisation facilitates clinical collaboration across organisations and regions, allowing images and patient data to be shared in real time to create a global community of consultants, educational institutions and specialists, who will have the ability to access shared images, AI and case data in real time. This will help to reduce the time to diagnosis and improve patient outcomes, as well as easing the burden when the demand for histopathologists outstrips the supply.
Dynamyx™ software is a vendor agnostic, end-to-end digital pathology solution, offering an open architecture that can be seamlessly integrated with scanners and LIMS. Dynamyx™ software connects workflow and case management tools with image evaluation and AI solutions. This significantly simplifies the workflow, as everything can be found in one highly functional and user-friendly package. In addition, AI can greatly improve the speed and accuracy of clinical decision making through analysis of objective, quantitative data. Fujifilm supports digital pathology, helping to streamline the transition into the digital era by providing a synergistic portfolio of technologies that help to unify, store, analyse and visualise clinical data.
Tim Wing, Head of Digital Pathology at FUJIFILM Europe, explained: “Fujifilm has been a part of the healthcare industry for a long time, and is now a global player in digital pathology. We are very excited to be exhibiting at ECP, and believe that Dynamyx™ software is an excellent system which, when combined with our complete suite of Fujifilm digital imaging products, will support rapid dissemination of data to clinicians. This will enable faster, more accurate diagnoses and, ultimately, improve patient outcomes.”